Skip to main content
Delic Holdings Corp. logo

Delic Holdings Corp. — Investor Relations & Filings

Ticker · DELCF ISIN · CA24689E1079 LEI · 8945004HTB9451S6LV82 CSE Human health and social work activities
Open in API
Filings indexed 264 across all filing types
Latest filing 2022-05-16 Regulatory Filings
Country CA Canada
Listing CSE DELCF

About Delic Holdings Corp.

https://thedelic.com

Delic Holdings Corp. is a psychedelic wellness corporation committed to delivering safe, legal, and science-backed benefits. The company operates an integrated ecosystem spanning media, science, and health services. Its core business involves owning and operating a chain of psychedelic wellness clinics, establishing one of the largest infrastructures in the sector. Delic provides various medicines and treatments, aiming to improve access to health benefits. Additionally, the company focuses on developing intellectual property and manages "The Delic," a creative platform dedicated to reframing the public conversation surrounding new medicines and treatments.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a default status update from Delic Holdings Corp regarding the delay in filing their annual financial statements and management's discussion and analysis for the fiscal year ended December 31, 2021. It references National Policy 12-203 related to management cease trade orders due to late filings. The document does not contain the actual annual report or financial statements but discusses the delay and regulatory status. It is a regulatory announcement about the filing status and compliance, not the report itself. The document length is 5519 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and status update rather than an Annual Report (10-K) or Report Publication Announcement (RPA).
2022-05-16 English
News release - English.pdf
Regulatory Filings
2022-05-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the introduction of a new therapy (NAD+ infusion therapy) by Ketamine Wellness Centers, a subsidiary of Delic Holdings Corp. It provides details about the therapy, its benefits, and the company's operations. There are no financial statements, regulatory filings, or detailed financial data presented. The document is a corporate announcement about a new service offering rather than a financial report, management discussion, or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Investor Presentation. It is best classified as a Regulatory Filing (RNS) since it is a general corporate announcement that does not fit other specific categories.
2022-05-04 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release announcing the late filing of the company's annual financial statements and management's discussion and analysis (MD&A) for the fiscal year ended December 31, 2021. It mentions the delay in audit completion and the application for a management cease trade order (MCTO). The document does not contain the actual annual report or financial statements but rather informs about the delay and regulatory compliance status. It is an announcement related to regulatory filings and compliance rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS). The document length is 5332 characters, which is relatively short and consistent with an announcement rather than a full report.
2022-05-04 English
Other.pdf
Regulatory Filings Classification · 100% confidence The document is an official authorization letter from Health Canada granting permission to Delic Labs Inc. to possess and use restricted drugs (psilocybin and psilocin) for scientific research purposes. It details conditions, limitations, record-keeping requirements, and compliance obligations under the Food and Drug Regulations. There are no financial statements, management discussions, or corporate governance information. The document is regulatory in nature, related to compliance and authorization for controlled substances research, and does not fit into financial or corporate filing categories such as Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement or a certification but a formal regulatory authorization. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory documents that do not fit other categories.
2022-04-29 English
Other.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from Health Canada authorizing the requisition of controlled substances for scientific purposes. It includes specific quantities and authorization details but does not contain any financial data, company performance information, or regulatory filings related to corporate financial or governance matters. It is not a financial report, announcement, or any of the specified filing types related to corporate filings. Therefore, it falls outside the typical categories and should be classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2022-04-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.